Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 8/31/21 → 4/24/23 |
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Munker, Reinhold (PI)